KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America.

Tarek El Hindi, Maria Theresa Alera, Lulu Bravo, Edson Duarte Moreira, Reynaldo Dietze, Ana Lucia Oliveira, Veerachai Watanaveeradej, Yuan Zhao, Ivo Sonderegger, Vianney Tricou, Nicolas Folschweiller, Shibadas Biswal

J Infect Dis 231(6) e1160-e1169

PMID40100744
PMCIDPMC12247829
DOI10.1093/infdis/jiaf145
发表日期2025-03-18
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other。
摘要

摘要

BACKGROUND: TAK-003 has been shown to be well tolerated and effective against symptomatic dengue disease and hospitalization, irrespective of baseline serostatus. Most infections are asymptomatic/subclinical. This study assessed whether TAK-003 could protect against asymptomatic/subclinical infections by evaluating increased neutralizing antibody (NAb) titers after natural infection. METHODS: DEN-301 (NCT02747927) is a phase 3 trial among 4- to 16-year-old participants who received 2 doses of TAK-003 or placebo 3 months apart. These exploratory analyses used NAb measured during the trial. As no well-accepted definition for asymptomatic infection exists, 3 algorithms were evaluated: (1) 4-fold increase in NAb, (2) 4-fold increase in NAb and a minimum titer of 40, and (3) 4-fold increase in NAb and a minimum titer of 4-fold lower limit of quantification. Months 4 to 9, months 9 to 15, and months 15 to 27 after first vaccination were analyzed. RESULTS: NAbs from 3765 participants were analyzed. From months 4 to 9, vaccine efficacy (VE) against asymptomatic infection was 51.1% (95% CI, 30.4%-65.6%), 36.1% (95% CI, 6.7%-56.3%), and 27.3% (95% CI, -8.2% to 51.2%) for algorithms 1, 2, and 3, respectively. VE per algorithms 1, 2, and 3 was 54.8% (95% CI, 28.8%-71.3%), 47.9% (95% CI, 16.8%-67.4%), and 44.3% (95% CI, 9.9%-65.6%) in participants with baseline seropositivity and 44.4% (95% CI, 2.1%-68.4%), 4.6% (95% CI, -85.1% to 50.8%), and -29.3% (95% CI, -172.1% to 38.6%) in those with baseline seronegativity. VE against asymptomatic infection gradually decreased from months 4 to 9 to months 9 to 15 and from months 9 to 15 to months 15 to 27. CONCLUSIONS: The variability in VE algorithms indicates challenges in accurately assessing VE against asymptomatic infections. TAK-003 had a modest impact on asymptomatic dengue infections in the first months postvaccination, mainly in participants with baseline seropositivity.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Participants received 2 doses of TAK-003 or placebo at months 0 and 3, and blood samples were collected to assess neutralizing antibody titers from the safety and immunogenicity subset in the DEN301 trial at baseline and months 4, 9, 15, and 27 from the per-protocol set for immunogenicity.
非 KM Figure
Figure 2Figure 2. Vaccine efficacy of TAK-003 against asymptomatic dengue infection from months 4 to 9. Algorithm 1, ≥4-fold increase in neutralizing antibodies; algorithm 2, ≥4-fold increase in neutralizing antibodies + ≥40; algorithm 3, ≥4-fold increase in neutralizing antibodies + minimum titer of 4× lower limit of quantification. Percentage of asymptomatic infection is based on the number of participants evaluated in the per-protocol set for immunogenicity. a Placebo, n = 984; TAK-003, n = 2004. b Placebo, n = 711; TAK-003, n = 1446. c Placebo, n = 273; TAK-003, n = 558.
非 KM Figure
Figure 3Figure 3. Vaccine efficacy of TAK-003 against asymptomatic dengue infection from months 9 to 15. Algorithm 1, ≥4-fold increase in neutralizing antibodies; algorithm 2, ≥4-fold increase in neutralizing antibodies + ≥40; algorithm 3, 4-fold increase in neutralizing antibodies + minimum titer of 4× lower limit of quantification. Percentage of asymptomatic infection is based on the number of participants evaluated in the per-protocol set for immunogenicity. a Placebo, n = 1022; TAK-003, n = 2055. b Placebo, n = 738; TAK-003, n = 1495. c Placebo, n = 284; TAK-003, n = 560.
非 KM Figure
Figure 4Figure 4. Vaccine efficacy of TAK-003 against asymptomatic dengue infection from months 15 to 27. Algorithm 1, ≥4-fold increase in neutralizing antibodies; algorithm 2, ≥4-fold increase in neutralizing antibodies + ≥40; algorithm 3, ≥4-fold increase in neutralizing antibodies + minimum titer of 4× lower limit of quantification. Percentage of asymptomatic infection is based on the number of participants evaluated in the per-protocol set for immunogenicity. a Placebo, n = 880; TAK-003, n = 1777. b Placebo, n = 638; TAK-003, n = 1337. c Placebo, n = 242; TAK-003, n = 440.
非 KM Figure
Figure 5Figure 5. Distribution of neutralizing antibody titer fold increases among participants, excluding virologically confirmed dengue cases, between months 4 and 27 (any increase from months 4 to 9, months 9 to 15, or months 15 to 27 in the per-protocol set for immunogenicity) among TAK-003 vs placebo in baseline participants who were seropositive and seronegative. Participants with increased antibody titers for at least 1 serotype were included in the analysis and are demonstrated in this figure. The algorithms analyzed in this study were based on at least a 4-fold increase in neutralizing antibody titers. The table insert shows the mean and median values of participants who met this threshold. a Virologically confirmed dengue cases were excluded from the analysis, as described in the Methods.
非 KM Figure